53例嗅神经母细胞瘤的临床分析

Chen Yan-Feng, Yang An-Kui, Zhang Quan, Ouyang Dian, Chen Wen-Kuan, Chen Fu-Jin

State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P. R. China.

Ai Zheng. 2009 Mar;28(3):308-11.

BACKGROUND AND OBJECTIVE

The prognosis of esthesioneuroblastoma (ENB) patients is poor. This study was to analyze prognostic factors and explore a rational treatment for ENB.

METHODS

Clinical data of 53 ENB patients, treated at Sun Yat-sen University Cancer Center from 1980 to 2003, were analyzed retrospectively. The correlation of prognostic factors to clinical features and treatment approaches were analyzed using the Kaplan-Meier method. Efficacy of different treatment modalities was compared.

RESULTS

The five-year overall survival (OS) was 41% of all ENB patients. The five-year OS of the surgery group, radiotherapy group, chemotherapy group, surgery combined with radiotherapy and (or) chemotherapy group, chemoradiotherapy were 42%, 38%, 0, 56%, 0, respectively, which were statistically significant (p<0.05). The five-year OS of Kadish stage A, B, C patients were 100%, 37%, 31%, respectively, which were statistically significant among these three subgroups which (p<0.05). The recurrence rate over the entire period was 51%. The five-year OS of the recurrence group and recurrence-free group were 42% and 48%, respectively, without significant differences (p>0.05).

CONCLUSIONS

ENB is a malignant tumor with high rates of locoregional recurrence and distant metastasis. Surgery-based multimodality is a relatively reasonable method. The prognosis of ENB is associated with the clinical stage and treatment modalities.

背景与目的

嗅神经母细胞瘤（ENB）患者预后较差。本研究旨在分析预后因素并探索ENB的合理治疗方法。

方法

回顾性分析1980年至2003年在中山大学肿瘤防治中心接受治疗的53例ENB患者的临床资料。采用Kaplan-Meier法分析预后因素与临床特征及治疗方法的相关性。比较不同治疗方式的疗效。

结果

所有ENB患者的五年总生存率（OS）为41%。手术组、放疗组、化疗组、手术联合放疗和（或）化疗组、放化疗组的五年OS分别为42%、38%、0、56%、0，差异有统计学意义（p<0.05）。Kadish A、B、C期患者的五年OS分别为100%、37%、31%，这三个亚组之间差异有统计学意义（p<0.05）。整个研究期间的复发率为51%。复发组和无复发组的五年OS分别为42%和48%，差异无统计学意义（p>0.05）。